Cargando…

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

BACKGROUND: In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Michelle L, Motsch, Johann, Kaye, Keith S, File, Thomas M, Boucher, Helen W, Vendetti, Neika, Aggrey, Angela, Joeng, Hee-Koung, Tipping, Robert W, Du, Jiejun, DePestel, Daryl D, Butterton, Joan R, Paschke, Amanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052751/ https://www.ncbi.nlm.nih.gov/pubmed/32154325 http://dx.doi.org/10.1093/ofid/ofaa054

Ejemplares similares

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
por: Motsch, Johann, et al.
Publicado: (2020)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
por: Losada, Maria C, et al.
Publicado: (2020)

597. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates: SMART United States 2016–2018
por: Lob, Sibylle, et al.
Publicado: (2019)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
por: Titov, Ivan, et al.
Publicado: (2020)

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
por: Campanella, Toni A, et al.
Publicado: (2020)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
por: Kurihara, Dai, et al.
Publicado: (2022)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
por: Young, Katherine, et al.
Publicado: (2019)

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
por: Bhagunde, Pratik, et al.
Publicado: (2019)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018)

1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017
por: Lob, Sibylle, et al.
Publicado: (2018)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019
por: Lob, Sibylle H, et al.
Publicado: (2021)

Upstream region of OprD mutations in imipenem-resistant and imipenem-sensitive Pseudomonas isolates
por: Kiani, Masoumeh, et al.
Publicado: (2021)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
por: Sahra, Syeda, et al.
Publicado: (2021)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
por: Wang, Leilei, et al.
Publicado: (2023)

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
por: Papp-Wallace, Krisztina M., et al.
Publicado: (2023)

2160. Emergence of INDEL Mutations in KPC-2: Insights into Ceftazidime-Avibactam and Imipenem-Relebactam Efficacy
por: Brunetti, Florencia, et al.
Publicado: (2023)

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Antimicrobial Resistance Determinants in Imipenem-nonsusceptible Acinetobacter calcoaceticus-baumannii Complex Isolated in Daejeon, Korea
por: Sung, Ji Youn, et al.
Publicado: (2011)

Emergence of ST463 exoU-Positive, Imipenem-Nonsusceptible Pseudomonas aeruginosa Isolates in China
por: Zhu, Ying, et al.
Publicado: (2023)

Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dh8qag1taqis0l1qj3se6gm254